Ignite Creation Date:
2024-05-06 @ 3:22 PM
Last Modification Date:
2024-10-26 @ 1:48 PM
Study NCT ID:
NCT04614636
Status:
TERMINATED
Last Update Posted:
2023-09-21
First Post:
2020-10-29
Brief Title:
FT538 in Subjects With Advanced Hematologic Malignancies
Sponsor:
Fate Therapeutics
Organization:
Fate Therapeutics
Study Overview
Official Title:
A Phase I Open-Label Multicenter Study of FT538 as Monotherapy in RelapsedRefractory Acute Myelogenous Leukemia and in Combination With Monoclonal Antibodies in RelapsedRefractory Multiple Myeloma
Status:
TERMINATED
Status Verified Date:
2023-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
This study was terminated by the Sponsor
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase I dose-finding study of FT538 as monotherapy in acute myeloid leukemia AML and in combination with monoclonal antibodies in multiple myeloma MM The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None